Evidence map›Paper›PMID 40909221›Full record

ReviewFrontiers in bioengineering and biotechnology2025

Responsive biomaterials for therapeutic strategies of hepatocellular carcinoma.

Xun Liao, Junxiu Zhou, Liang Feng, Lian Wang, Hong Wu, Li Jiang, Yuanyuan Jia, Qingbin Wu, Shu Shen

Abstract readReview
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xun LiaoTianfu Jincheng Laboratory, Chengdu, China.
Junxiu ZhouTianfu Jincheng Laboratory, Chengdu, China.
Liang FengTianfu Jincheng Laboratory, Chengdu, China.
Lian WangTianfu Jincheng Laboratory, Chengdu, China.
Hong WuTianfu Jincheng Laboratory, Chengdu, China.
Li JiangTianfu Jincheng Laboratory, Chengdu, China.
Yuanyuan JiaTianfu Jincheng Laboratory, Chengdu, China.
Qingbin WuColorectal Cancer Center, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.
Shu ShenDepartment of Liver Surgery, Liver Transplantation Center, West China Hospital of Sichuan University, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) represents a major global health burden due to its high recurrence and mortality rates. For patients with advanced HCC and compromised liver function, Pharmacotherapy has become the primary approach due to the limited efficacy of conventional treatments (e.g., surgical resection/ablation). Nevertheless, traditional anti-tumor agents suffer from poor target selectivity, systemic toxicity, and the emergence of drug resistance. To overcome these challenges, stimuli-responsive biomaterials have been developed as innovative strategies to improve HCC management. These advanced materials enable precise spatiotemporal control of drug delivery and release, thereby enhancing therapeutic efficacy while reducing side effects. This review provides a systematic overview of stimuli-responsive biomaterials, classified based on their responses to endogenous cues (e.g., pH, enzymes, and redox conditions) and exogenous stimuli (e.g., light and magnetic fields). These materials show great potential in overcoming biological barriers in HCC therapy and enhancing drug delivery efficiency, thereby paving the way for future clinical applications. By analyzing recent advances, this review highlights the potential of stimuli-responsive biomaterials in advancing therapeutic strategies for HCC. Integrating these materials into HCC therapy may significantly enhance patient outcomes and revolutionize existing treatment paradigms.

Indexed as

cancer therapydrug deliveryhepatocellular carcinoma (HCC)responsive biomaterialstumor microenvironment

Identifiers

PMID40909221
PMCPMC12405289

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.